Eli Lilly and Company (NYSE:LLY) Shares Sold by Ameliora Wealth Management Ltd.

by · The Cerbat Gem

Ameliora Wealth Management Ltd. decreased its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 10.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,099 shares of the company’s stock after selling 488 shares during the quarter. Eli Lilly and Company accounts for approximately 1.5% of Ameliora Wealth Management Ltd.’s holdings, making the stock its 19th largest position. Ameliora Wealth Management Ltd.’s holdings in Eli Lilly and Company were worth $3,631,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Able Wealth Management LLC acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $75,000. Raleigh Capital Management Inc. lifted its stake in Eli Lilly and Company by 241.9% in the fourth quarter. Raleigh Capital Management Inc. now owns 506 shares of the company’s stock valued at $295,000 after buying an additional 358 shares during the last quarter. Sierra Summit Advisors LLC acquired a new position in shares of Eli Lilly and Company during the fourth quarter valued at $3,726,000. Integrated Advisors Network LLC increased its holdings in shares of Eli Lilly and Company by 2.3% in the 4th quarter. Integrated Advisors Network LLC now owns 11,780 shares of the company’s stock worth $6,867,000 after acquiring an additional 270 shares during the period. Finally, Centaurus Financial Inc. lifted its position in Eli Lilly and Company by 1.8% in the 4th quarter. Centaurus Financial Inc. now owns 2,003 shares of the company’s stock valued at $1,167,000 after purchasing an additional 35 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Up 2.3 %

Shares of Eli Lilly and Company stock traded up $21.37 during trading on Friday, hitting $932.06. 2,293,874 shares of the stock traded hands, compared to its average volume of 3,009,544. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The stock has a market cap of $885.83 billion, a P/E ratio of 137.27, a PEG ratio of 2.79 and a beta of 0.42. Eli Lilly and Company has a twelve month low of $547.61 and a twelve month high of $972.53. The company has a fifty day moving average price of $910.84 and a two-hundred day moving average price of $852.86.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The company had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. Equities research analysts predict that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on LLY shares. Jefferies Financial Group raised their target price on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research report on Monday, June 24th. Truist Financial upped their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a report on Thursday. Berenberg Bank boosted their price target on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $885.00 price target on shares of Eli Lilly and Company in a research note on Monday, September 16th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $1,025.00 target price on shares of Eli Lilly and Company in a research report on Thursday, October 3rd. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $979.29.

View Our Latest Stock Report on LLY

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Read More